|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2008-7-22
|
|
pubmed:abstractText |
COPD exacerbations are associated with significant morbidity and mortality. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of fluticasone propionate/salmeterol 250/50 and salmeterol 50 microg twice daily on moderate to severe exacerbations.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0954-6111
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
102
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1099-108
|
|
pubmed:meshHeading |
pubmed-meshheading:18614347-Adult,
pubmed-meshheading:18614347-Aged,
pubmed-meshheading:18614347-Albuterol,
pubmed-meshheading:18614347-Androstadienes,
pubmed-meshheading:18614347-Bronchodilator Agents,
pubmed-meshheading:18614347-Double-Blind Method,
pubmed-meshheading:18614347-Drug Combinations,
pubmed-meshheading:18614347-Female,
pubmed-meshheading:18614347-Forced Expiratory Volume,
pubmed-meshheading:18614347-Humans,
pubmed-meshheading:18614347-Male,
pubmed-meshheading:18614347-Middle Aged,
pubmed-meshheading:18614347-Pulmonary Disease, Chronic Obstructive,
pubmed-meshheading:18614347-Quality of Life,
pubmed-meshheading:18614347-Smoking
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
|
|
pubmed:affiliation |
Pulmonary Research Institute of Southeast Michigan, 28807 Eight Mile Road, Suite 103, Livonia, MI 48152, USA. garytferguson@msn.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
